Indian drug manufacturer Ranbaxy will pay $420,000 to Idaho state, USA, as a part of $500 million settlement for selling inferior quality medicines, which were manufactured between April 2003 and September 2010, in 26 states of USA. The company will also pay $150 million for violating the US Food, Drug and Cosmetic Act.